| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
183 |
| issn |
2577-171X |
| issueIdentifier |
4 |
| pageRange |
183-183 |
| publicationName |
IJU Case Reports |
| startingPage |
183 |
| bibliographicCitation |
Yamamoto Y. Editorial Comment to Tumor lysis syndrome following cabazitaxel administration for metastatic castration-resistant prostate cancer: A case report. IJU Case Rep. 2019 Jul;2(4):183. PMID: 32743406; PMCID: PMC7292127. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1271-3521 |
| date |
2019-05-09^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1002/iju5.12080
https://pubmed.ncbi.nlm.nih.gov/32743406
https://pubmed.ncbi.nlm.nih.gov/PMC7292127 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/49421
https://portal.issn.org/resource/ISSN/2577-171X |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Editorial Comment to Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9854073
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9689
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 |